$CBIS To Release 7 Cannabinoid-Based Animal Care P
Post# of 44960
Posted On: 11/11/2015 8:43:02 AM
$CBIS To Release 7 Cannabinoid-Based Animal Care Products Thru Its Wholly Owned Subsidiary, Equi-Pharm, LLC
http://finance.yahoo.com/news/product-market-...51466.html
COLORADO SPRINGS, CO--(Marketwired - Nov 11, 2015) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that its formulation and market tests are completed and Cannabis Science is set to release seven original cannabinoid-based animal care products through its wholly owned subsidiary, Equi-Pharm, LLC.
Following the recent acquisition of Equi-Pharm, LLC the Company has already expanded the company's product offerings beyond its flagship equestrian lines to include original cannabinoid-based products for other types of animals as well. With all product testing completed and such a favorable response, the Company is now diligently working to launch an e-commerce website to allow direct-to-consumer sales of these seven unique, cannabinoid-infused, animal care products. The full-featured, finished website is scheduled to launch on December 1st, 2015.
Currently, Equi-Pharm relies on its five local distributors for nearly all of its sales. They have not developed strong internet-based sales channels to date, and they have relied nearly exclusively on equestrian markets. Cannabis Science recognizes the potential in expanding total attainable market (TAM) for the company's cannabinoid-infused animal care products by expanding their product offerings to include other types of pets and creating an easy-to-use e-commerce website to drive sales. This will help reduce overhead and increase revenue generation beyond Equi-Pharm's current operations.
"This acquisition allows Cannabis Science, Inc. to leverage its expertise with the cannabinoids to create a unique niche in the pet healthcare industry, which will allow them to capture an unsaturated market segment. We are excited to roll out our new cannabinoid-based products in the U.S. and even more excited about entering the $60 billion pet healthcare industry," said Dana Kennamer, Equi-Pharm, LLC, VP of Operations.
http://finance.yahoo.com/news/product-market-...51466.html
COLORADO SPRINGS, CO--(Marketwired - Nov 11, 2015) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that its formulation and market tests are completed and Cannabis Science is set to release seven original cannabinoid-based animal care products through its wholly owned subsidiary, Equi-Pharm, LLC.
Following the recent acquisition of Equi-Pharm, LLC the Company has already expanded the company's product offerings beyond its flagship equestrian lines to include original cannabinoid-based products for other types of animals as well. With all product testing completed and such a favorable response, the Company is now diligently working to launch an e-commerce website to allow direct-to-consumer sales of these seven unique, cannabinoid-infused, animal care products. The full-featured, finished website is scheduled to launch on December 1st, 2015.
Currently, Equi-Pharm relies on its five local distributors for nearly all of its sales. They have not developed strong internet-based sales channels to date, and they have relied nearly exclusively on equestrian markets. Cannabis Science recognizes the potential in expanding total attainable market (TAM) for the company's cannabinoid-infused animal care products by expanding their product offerings to include other types of pets and creating an easy-to-use e-commerce website to drive sales. This will help reduce overhead and increase revenue generation beyond Equi-Pharm's current operations.
"This acquisition allows Cannabis Science, Inc. to leverage its expertise with the cannabinoids to create a unique niche in the pet healthcare industry, which will allow them to capture an unsaturated market segment. We are excited to roll out our new cannabinoid-based products in the U.S. and even more excited about entering the $60 billion pet healthcare industry," said Dana Kennamer, Equi-Pharm, LLC, VP of Operations.
(0)
(0)